The Hyperoxaluria therapeutic landscape is witnessing a transformative shift, driven by cutting-edge research and the emergence of targeted therapies aimed at addressing the root causes of oxalate overproduction. Companies such as Arbor Biotechnologies, META Pharmaceuticals, and Biocodex are at the forefront of innovation, leveraging advanced technologies including gene editing and metabolic modulation to reshape treatment paradigms.

 

DelveInsight’s, “Hyperoxaluria Pipeline Insight, 2026” report provides comprehensive insights into 3+ companies and 3+ pipeline drugs within the Hyperoxaluria pipeline ecosystem. The report offers a detailed evaluation of pipeline drug profiles across clinical and nonclinical stages, along with an in-depth therapeutic assessment based on product type, development stage, route of administration, and molecule type. It also sheds light on inactive and discontinued programs, offering a holistic view of the evolving R&D landscape.

 

Explore the complete Hyperoxaluria pipeline landscape and future growth opportunities here: Hyperoxaluria Clinical Trial Analysis

 

Key Takeaways from the Hyperoxaluria Pipeline Report

• The Hyperoxaluria pipeline includes 3+ active therapeutic candidates across multiple stages of development.
• Increasing focus on gene editing and metabolic pathway modulation is redefining treatment strategies.
• Novel approaches targeting oxalate biosynthesis pathways are gaining traction.
• Strategic collaborations and licensing agreements are accelerating drug development timelines.
• The pipeline reflects a shift toward precision medicine and one-time curative therapies.
• Clinical trials are exploring innovative endpoints and biomarkers for improved efficacy assessment.
• Diverse molecule types, including gene therapies, small molecules, and peptides, are being investigated.
• In April 2026, Alnylam Pharmaceuticals announced results of BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
• In February 2026, Arbor Biotechnologies announced results of a Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)
• In November 2025, YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for YOLT-203, an in vivo gene-editing therapy for the treatment of Primary Hyperoxaluria Type 1 (PH1).

 

Gain early access to emerging therapies and clinical advancements shaping Hyperoxaluria treatment: Hyperoxaluria Pipeline Outlook

 

Understanding Hyperoxaluria: A Progressive and Underdiagnosed Renal Disorder

Hyperoxaluria is a metabolic condition characterized by excessive urinary excretion of oxalate, a key contributor to kidney stone formation—particularly calcium oxalate nephrolithiasis. Kidney stones affect approximately 10% of the global population, with nearly 80% composed of calcium, and calcium oxalate stones representing the most prevalent subtype. Even minor elevations in urinary oxalate levels can significantly increase the risk of crystallization, underscoring the clinical importance of maintaining oxalate homeostasis.

The condition often remains silent in its early stages but typically manifests through recurrent kidney stone episodes. Patients commonly present with severe flank pain or renal colic radiating to the groin, accompanied by hematuria, dysuria, and increased urinary frequency. Additional symptoms such as nausea, vomiting, and cloudy or foul-smelling urine may occur, particularly during acute stone events or associated infections.

Hyperoxaluria arises from multiple etiologies, including excessive dietary oxalate intake, increased endogenous production in the liver, and enhanced conversion from vitamin C. Oxalate is absorbed in the gastrointestinal tract and excreted by the kidneys, where it binds with calcium to form poorly soluble crystals. These crystals initiate stone formation through nucleation, growth, aggregation, and retention in renal tubules.

Persistent oxalate accumulation can lead to nephrocalcinosis, characterized by crystal deposition in renal tissue. This triggers inflammation, tubular damage, and fibrosis, ultimately leading to progressive renal impairment. In severe cases, the condition may advance to end-stage renal disease (ESRD), necessitating dialysis or transplantation.

 

Evolving Hyperoxaluria Pipeline Landscape: Innovation at the Core

The Hyperoxaluria pipeline is gaining momentum, fueled by advancements in molecular biology, genetic engineering, and precision medicine. Emerging therapies are increasingly focused on targeting the biochemical pathways responsible for oxalate overproduction, offering the potential for long-term disease control or even cure.

 

DelveInsight’s analysis reveals that 3+ companies are actively engaged in developing innovative therapies for Hyperoxaluria, with 3+ pipeline candidates spanning early-stage discovery to mid-stage clinical development. These efforts are aimed at overcoming limitations of existing therapies, such as poor efficacy, safety concerns, and lack of targeted action.

 

Hyperoxaluria Emerging Drugs Profile

ABO-101: Arbor Biotechnologies

ABO-101 is a groundbreaking investigational therapy designed as a one-time gene editing treatment targeting the HAO1 gene in the liver. Utilizing a lipid nanoparticle (LNP) delivery system licensed from Acuitas Therapeutics, the therapy encapsulates mRNA encoding a CRISPR Cas12i2 nuclease and a guide RNA specific to the HAO1 gene.

By permanently disrupting HAO1 function, ABO-101 aims to significantly reduce oxalate production at its source. The therapy has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the FDA, underscoring its potential impact in treating primary Hyperoxaluria type 1 (PH1). It is currently being evaluated in Phase I/II clinical trials, positioning it as one of the most promising candidates in the pipeline.

 

META 001 PH: META Pharmaceuticals

META 001 PH is an emerging therapeutic candidate focused on modulating metabolic pathways involved in oxalate synthesis. The drug is currently in early-stage development and aims to provide a targeted approach to reducing systemic oxalate levels. Its mechanism is designed to complement existing therapies while offering improved safety and efficacy.

 

Stiripentol: Biocodex

Originally developed for neurological indications, Stiripentol is being repurposed for Hyperoxaluria treatment. The drug is believed to influence metabolic pathways that indirectly reduce oxalate production. Its repositioning highlights the growing interest in leveraging existing molecules for new therapeutic applications.

 

Explore detailed drug profiles, clinical trial updates, and mechanisms of action: Hyperoxaluria Competitive Landscape

 

Hyperoxaluria Pipeline Segmentation and Therapeutic Assessment

DelveInsight’s report provides a comprehensive segmentation of pipeline therapies based on development stage, route of administration, and molecule type.

Hyperoxaluria Clinical Trial Phases

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Preclinical and discovery-stage candidates
• Inactive and discontinued programs

 

Hyperoxaluria Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Hyperoxaluria Molecule Types

• Small molecules
• Monoclonal antibodies
• Peptides
• Gene therapies
• Recombinant fusion proteins
• Polymer-based therapies

 

Hyperoxaluria Product Types

• Monotherapy
• Combination therapy
• Mono/Combination approaches

This diverse therapeutic landscape reflects the complexity of Hyperoxaluria and the need for multifaceted treatment strategies.

 

Stay ahead with comprehensive insights into clinical trials, partnerships, and innovation trends: Hyperoxaluria Clinical Trial and FDA Approval

 

Hyperoxaluria Clinical Trial and Development Activities

The Hyperoxaluria pipeline is characterized by increasing clinical trial activity and strategic collaborations. Companies are actively pursuing partnerships with academic institutions and biotechnology firms to accelerate innovation and expand their research capabilities.

Key players such as Arbor Biotechnologies are leading the charge with next-generation gene editing therapies, while others are exploring metabolic modulation and drug repurposing strategies. These collaborative efforts are expected to enhance the speed and efficiency of drug development.

 

Hyperoxaluria Market Drivers, Challenges, and Future Outlook

The growth of the Hyperoxaluria pipeline is driven by several key factors, including increasing disease awareness, advancements in diagnostic technologies, and the rising demand for targeted therapies. The growing burden of kidney stone disease and its associated complications further underscores the need for effective treatment options.

However, challenges such as limited patient populations, high development costs, and regulatory complexities continue to hinder progress. Additionally, the lack of standardized biomarkers and variability in disease presentation pose challenges in clinical trial design.

Looking ahead, the integration of gene editing technologies, biomarker discovery, and precision medicine is expected to revolutionize Hyperoxaluria treatment. Several promising therapies are advancing through clinical trials, with the potential to offer long-term disease control and improved patient outcomes.

 

Access the full report to gain strategic insights and stay ahead in the Hyperoxaluria market: Hyperoxaluria Companies and Medication

 

Scope of the Hyperoxaluria Pipeline Report

• Coverage: Global
• Key Hyperoxaluria Companies: Arbor Biotechnologies, META Pharmaceuticals, Biocodex
• Key Hyperoxaluria Therapies: ABO-101, META 001 PH, Stiripentol
• Hyperoxaluria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hyperoxaluria Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

 

Key Questions Answered

• How many companies are developing Hyperoxaluria therapies?
• What is the distribution of drugs across development stages?
• What are the key collaborations and licensing activities?
• What novel technologies are being explored?
• What are the ongoing clinical trials and their status?
• Which drugs have received regulatory designations?

 

Unlock the Future of Hyperoxaluria Treatment

The Hyperoxaluria pipeline is entering a phase of rapid evolution, with innovative therapies poised to address longstanding unmet needs. As research continues to advance, the integration of cutting-edge technologies and collaborative efforts will play a crucial role in shaping the future of treatment.

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting